Of course, all patients with HF should be treated with medications that have been shown to improve survival and reduce the risk of HF hospitalizations, namely angiotensin-converting enzyme inhibitors (ACE-I), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter 2 (SGLT2) inhibitors (recommendations depend on HF phenotype) [2]. Here, SLC5A2 is linked to hydrops fetalis.